Overview

This trial is active, not recruiting.

Condition her2-positive breast cancer
Treatments tdm1, brain sequential rt
Phase phase 1
Sponsor Centre Val d'Aurelle - Paul Lamarque
Start date February 2014
End date February 2017
Trial size 36 participants
Trial identifier NCT02135159, VA2012/38

Summary

The purpose of this study is to determine the optimal sequences of combined trastuzumab emtansine (T-DM1) and whole-brain radiotherapy in patients presenting brain metastases from HER2-positive breast cancer in terms of acute toxicities and blood/cerebrospinal fluid T-DM1 pharmacokinetics.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
tdm1 no other names
administration of the TDM1 by IV perfusion
brain sequential rt No other names
local RT
(Experimental)
Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
tdm1 no other names
administration of the TDM1 by IV perfusion
brain sequential rt No other names
local RT
(Experimental)
Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
tdm1 no other names
administration of the TDM1 by IV perfusion
brain sequential rt No other names
local RT
(Experimental)
T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
tdm1 no other names
administration of the TDM1 by IV perfusion
brain sequential rt No other names
local RT

Primary Outcomes

Measure
optimal sequences of combined treatment
time frame: 3 months

Secondary Outcomes

Measure
objective response
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Histologically confirmed invasive breast cancer with stage IV disease. 2. HER-2 positive primary tumor, defined as: IHC3+, or IHC2+ and ISH positive. 3. Non operable brain metastases (n ≥ 2) with at least one measurable CNS lesion ≥ 10 mm on T1-weighted gadolinium-enhanced MRI. 4. No stereotaxie radiotherapy indication 5. At least two weeks from any specific breast cancer treatment (such as Trastuzumab, chemotherapy, immunotherapy/biological response modifiers, endocrine therapy and radiotherapy). 6. Adequate hematologic function (ANC ≥1x109/L, platelets ≥100 000/L; Hb >10g/dL), renal function (creatinine ≤ 1.5x UNL) and hepatic function (albumin ≥2.5 g/dL; serum bilirubin ≤1.5x ULN unless due to Gilbert's syndrome; AST and ALT ≤ 5x ULN if documented liver metastasis or ≤ 3x ULN without liver metastasis). 7. At least 18 years old. 8. ECOG Performance Status of 0 to 2. 9. Life expectancy ≥ 3 months. 10. Potentially reproductive patients must agree to use an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product for women. Males able to father a child must practice adequate methods of birth control or practice complete abstinence from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment. 11. Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and/or urine pregnancy test 48 hours prior to the administration of the first study treatment. 12. Patients must be affiliated to a Social Security System. 13. Patient information and written informed consent form signed. Exclusion Criteria: 1. Previous whole brain radiotherapy (WBRT) or brain stereotaxie radiotherapy. 2. Planned or concurrent systemic treatment or radiation therapy (other than corticosteroid, bisphosphonates or mannitol). 3. Known contra-indication to MRI. 4. Active concurrent malignancy. If there is a history of prior malignancy, the patient must be disease free for at least 10 years. 5. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as : - infection, - cardiac disease such as uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within one year, LVEF ≤ 50%, - current active hepatic or renal disease 6. Pregnant women, women who are likely to become pregnant or are breast-feeding. 7. Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 8. Known hypersensibility to any component of T-DM1 9. Patients who received any other investigational drugs within the 30 days prior to the screening visit. 10. Individual deprived of liberty or placed under the authority of a tutor. 11. Leptomeningeal metastases diagnosed by MRI 12. Inclusion in another protocol within 30 days 13. Brain metastases with severe intracranial hypertension clinical signs 14. Other cancer except the known primary tumor or in situ cervix cancer or basocellular carcinoma

Additional Information

Official title A Phase I Study to Evaluate the Feasibility of Different Sequences of Combined Trastuzumab Emtansine (T-DM1) and Whole-brain Radiotherapy in Patients With Brain Metastases From HER2-positive Breast Cancer
Principal investigator David AZRIA
Description Determine the best sequences.
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by Centre Val d'Aurelle - Paul Lamarque.